| Similar Articles |
|---|
 |
The Motley Fool
November 1, 2010
Sean Williams |
Somaxon Pharmaceuticals: Bargain or Value Trap? A strong balance sheet and Procter & Gamble could make this a value play.   |
The Motley Fool
June 9, 2011
Brian Orelli |
Get Out of Here! $0.5 Million to License a Drug? Somaxon licenses rights to Silenor in Canada, South America, and Africa to Paladin. |
The Motley Fool
August 4, 2011
Sean Williams |
Somaxon's Bore of a Quarter Silenor sales fly out of the gate like molasses in winter. |
The Motley Fool
July 28, 2010
Jordan DiPietro |
3 Biotechs on Your Radar Screen It's not easy keeping track of all the drugs coming in and out of the development pipeline, but if you can stay up to date, you often have an advantage |
The Motley Fool
September 17, 2009
Brian Orelli |
Sleepless in Sanofi It's nothing but sleepless nights for sanofi-aventis, and there's no drug to cure it. |
The Motley Fool
January 26, 2006
Rich Smith |
Foolish Forecast: Procter & Gamble Lathers Up If P&G continues to highlight the Household Care and Beauty businesses from the home team, and the Blades & Razors and Duracell & Braun divisions from Gillette as its star players, wise investors should give this stock a glance. |
The Motley Fool
January 31, 2011
Andrew Bond |
A Consumer Giant That's on the Cutting Edge Procter & Gamble's innovation comes from many sources. |
The Motley Fool
September 12, 2007
Brian Orelli |
Butterflies Move Eastward Sepracor and GlaxoSmithKline ink a deal to market Lunesta worldwide. The market in Europe for sleep aids last year was about $500 million, but only about a quarter of insomnia sufferers are on medication, so there's certainly room for the market to grow. |
The Motley Fool
August 13, 2004
Charly Travers |
Smaller Market for Insomnia Drugs A market research report shows insurers might not cover some drugs for this condition. |
The Motley Fool
January 27, 2006
Stephen D. Simpson |
P&G Stocks Up on Profits Solid execution continues to be the hallmark of this consumer-goods giant. Investors, take note. |
The Motley Fool
October 31, 2007
Brian Orelli |
A Slimmer Sepracor The big-pharma company reduces its sales team after a government decision forces price cuts for one of its top drugs. Investors, take note. |
The Motley Fool
October 27, 2006
Brian Lawler |
Wake Up to Sepracor Its insomnia drug is taking hold, and sales of its other drug jumped, too. If Sepracor can slim down its marketing spending, earnings should skyrocket. Investors, take note. |
The Motley Fool
August 6, 2009
Colleen Paulson |
Procter & Gamble Fights the Tide Global currency fluctuations and declining volume hurt P&G's profits in the fourth quarter. |
The Motley Fool
November 9, 2006
Todd Wenning |
The Best Blue Chip for 2007: Procter & Gamble Investors, this omnipotent consumer staples firm is the best blue chip in the market. |
The Motley Fool
January 28, 2011
Matt Koppenheffer |
Procter & Gamble Shareholders Need Some Cheer Shares of Procter & Gamble take a dip after it announced fourth-quarter results. |
The Motley Fool
July 30, 2007
Brian Orelli |
Why Sepracor Investors Can't Sleep Shares of the drug maker were hammered after the company announced lower than expected earnings and a not so bright future. |
The Motley Fool
February 27, 2008
Colleen Paulson |
Making the Tough Decisions Delivering double-digit toothpaste and soap growth means that Procter & Gamble must be meticulous about cost control, and P&G has signaled once again that it will proactively manage its business to success. |
The Motley Fool
November 1, 2005
Nathan Parmelee |
A Small Surprise From P&G Proctor & Gamble delivers, just like it promised, releasing first-quarter earnings that were actually a penny ahead of expectations. |
The Motley Fool
January 31, 2007
Steven Mallas |
P&G Still Lets You Sleep at Night Procter & Gamble delivered its second-quarter results yesterday. The market didn't seem impressed; its shares traded slightly to the downside. Is there something wrong with P&G? |
The Motley Fool
October 26, 2010
Matt Koppenheffer |
Can Procter & Gamble Defeat the Private Labels? Can P&G's latest marketing push help it reinvigorate sales in its largest market? |
The Motley Fool
October 30, 2009
Mike Pienciak |
P&G Inches Forward Slowly, very slowly, Procter & Gamble is crawling out of consumer-staples purgatory. But don't be fooled -- the world's largest consumer products company has a long way to go before it reaches growth nirvana. |
The Motley Fool
October 1, 2009
Robert Steyer |
For Drugmakers, It's All In or Get Out The Solvay-Abbott deal illustrates why conglomerates are getting out of the prescription-drug business. |
The Motley Fool
July 16, 2010
Sean Sun |
Stock Cheat Sheet: Procter & Gamble If you're new to Procter & Gamble, consider this your cheat sheet to get introduced to the consumer products giant. |
The Motley Fool
April 13, 2006
John Reeves |
A Foolish Baby Shower: Procter & Gamble Few stocks have performed as well over the long term as Procter & Gamble. Clearly, this company is built to last. Investors, take note. |
BusinessWeek
July 25, 2005
Robert Barker |
P&G's $57 Billion Bargain Should it close, Procter & Gamble's $57 billion deal for Gillette is likely to stand as this year's biggest. Focusing on three different sets of numbers, for investors P&G stock looks like a bargain. |
The Motley Fool
August 4, 2010
Matt Koppenheffer |
Have You Sold Your Procter & Gamble Shares Yet? Procter & Gamble reported earnings that disappointed the market. |
The Motley Fool
November 2, 2006
Steven Mallas |
P&G Just Peachy Investors, you can count on Procter & Gamble to deliver the earnings goods. |
The Motley Fool
August 31, 2010
Matt Koppenheffer |
How Much Is Procter & Gamble Worth? Is Procter & Gamble's stock on sale? |
The Motley Fool
December 28, 2006
Michael Leibert |
Fool on the Street: P&G Still Going Strong Investors who believe that the consumer goods giant can achieve organic sales growth of 4% to 7% over the next few years might consider the current share price to be an attractive entry point to own a stake in an industry leader. |
The Motley Fool
August 25, 2009
Mike Pienciak |
Will P&G Ever Turn Around? Will the recently announced sale of its pharmaceutical business to specialty-drugs developer Warner Chilcott mark a turning point for Proctor & Gamble, or just another misstep? |
The Motley Fool
October 12, 2005
Steven Mallas |
P&G Gambles on Prosperity Shareholders will have a nice stock on their hands for a while. Procter & Gamble sees steady growth four years out. |
The Motley Fool
May 2, 2007
Timothy M. Otte |
P&G Loses the Expectations Game Analysts aren't impressed with the conglomerate's third-quarter results. Investors, take note. |
The Motley Fool
January 30, 2009
Colleen Paulson |
It's a Big World, P&G Global currency fluctuations eat into Procter & Gamble's quarterly earnings. |
BusinessWeek
January 17, 2005
Weintraub & Barrett |
Waking Up The Insomnia Market On Dec. 16, Sepracor Inc. won approval from the Food & Drug Administration to market Lunesta, a new sleep aid. Giddy investors pushed Sepracor's stock up 16%, to $60, in the two weeks following the news. |
CIO
August 24, 2009
Rick Swanborg |
How Procter & Gamble Got Employees to Use Social Networking at Work Procter & Gamble drove adoption of social networking tools by integrating them with existing work processes. |
The Motley Fool
May 12, 2004
Brian Gorman |
Procter & Gamble Bets on China The consumer products powerhouse looks like it's making all the right moves. |
The Motley Fool
January 22, 2010
Mike Pienciak |
Can P&G Be the Amazon.com of Consumer Staples? Management hopes a new online store will boosts sales and provide consumer insight. |
The Motley Fool
July 19, 2010
Eric Bleeker |
Procter & Gamble's Tricky Ambitions Can it maintain margins while moving further into value segments? |
The Motley Fool
January 29, 2004
Alyce Lomax |
All's Wella at P&G Wella's working, but will Procter & Gamble's stake in the German company help P&G take over the world? |
The Motley Fool
August 3, 2006
Steven Mallas |
A Prosperous P&G Procter & Gamble had a great year that was aided by the Gillette acquisition. This equity is a great long-term core holding; if you see it at an even higher yield, do yourself a favor and take a hard look at this stalwart operation. |
The Motley Fool
April 30, 2010
Mike Pienciak |
P&G Pays the Price for Growth Product discounting and increased ad spending held back profit growth at Proctor & Gamble. |
The Motley Fool
April 10, 2007
Brian Lawler |
Barr Issues a Challenge Barr challenges the patents on one of Sanofi's top drugs. |
BusinessWeek
January 26, 2004
Arelene Weintraub |
"Exploring New Paradigms in Sleep" Two top execs from Sanofi, maker of the popular drug Ambien, talk about the challenges of staying on top in the insomnia market. |
The Motley Fool
April 1, 2004
Bill Mann |
P&G Unloads Sunny D Procter & Gamble sells its juice-based drink brand to J.W. Childs. |
The Motley Fool
December 17, 2004
Brian Gorman |
Sepracor's Dream Drug? Investors should be awake to Lunesta's potential pitfalls. |
BusinessWeek
October 4, 2004
Berner et al. |
P&G Has Rivals In A Wringer Colgate and Unilever are hurting as Proctor & Gamble rolls out creative products and marketing. |
The Motley Fool
February 4, 2008
Timothy M. Otte |
Predictable Procter & Gamble Investors can find comfort in solid, predictable results like those from Procter & Gamble's second quarter. |
The Motley Fool
September 11, 2009
Mike Pienciak |
Procter & Gamble Caves In to the Recession The consumer products giant is cutting prices to lure back customers. |
The Motley Fool
May 5, 2006
Tim Beyers |
Wall Street Gets One Right Procter & Gamble's big sales and earnings gains aren't enough for investors. |
The Motley Fool
October 27, 2004
Alyce Lomax |
P&G Plows Along Investors got the jitters today, but Procter & Gamble's still strong. |
